Participant flow

A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2) · Source last updated 2024-03-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants who had disease progression during or following treatment with at least one platinum-containing chemotherapy regimen in the metastatic setting received atezolizumab 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of 21-day cycles until loss of clinical benefit or unmanageable toxicity.

   id

   FG000

   title

   Cohort 2: Participants With Second-line or Beyond Treatments

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         253

      type

      Death

   2. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Lost to Follow-up

   3. reasons

      1. group Id

         FG000

         num Subjects

         16

      type

      Withdrawal by Subject

   4. reasons

      1. group Id

         FG000

         num Subjects

         31

      type

      Study Terminated By Sponsor

   5. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Non-Compliance

   6. reasons

      1. group Id

         FG000

         num Subjects

         6

      type

      Physician Decision

   7. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Progression Of Disease

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         310

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         310

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

The analysis included data up to cutoff date 28 February 2023.

recruitment Details

The study is considered "Completed" because the planned study activities and analyses have been performed.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice